Inferra AI / Company / RDY
Dr Reddys Laboratories Ltd
RDY · Health Care
Last earnings Oct 23, 2026
Key results
Revenuequarter
5.6%
The business reported a revenue decline of 5.6% and an EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding period last year, as well as a provision of 240 crores for inventory and other costs associated with the recent semaglutide API related challenges.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Gross marginquarter
51.6%
The reported gross margin was 51.6% for Global Generics and 4.5% for PSAI.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Profit after tax attributable to equity holders of the parent for the quarter stood at 443 crores, which is US$47 million, a margin of 5.5% on revenues, before adjusting for the semaglutide API related provision mentioned earlier.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Our North America Generics business reported revenues of US$236 million for the quarter, accounting for 27% of our overall revenues and reflecting a decline of 41% year-on-year and a growth of 19% sequentially.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Our branded franchises including India, Emerging Markets and consumer health business in Nicotine Replacement Therapy or NRT, together account for 52%* of our overall revenues, and remain an important source of stable margins for the Company.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
5 Q1FY27 Earnings Conference Call Transcript July 22, 2026 Our Emerging Markets business recorded revenues of 1,833 crores, accounting for 23% of our overall revenues and reflecting a robust growth of 31% year-on-year and 2% quarter-on-quarter.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Revenues were broadly in line with the corresponding period last year and declined 3% sequentially, on account of price erosion as well as the impact of operating model changes post NRT integration explained by MVN, offsetting the contributions from new product launches in generics.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Our PSAI business reported revenues of US$91 million, accounting for 11% of the overall revenues.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
AI analysis
Q1 FY2027 · reported Jul 29, 2026
Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held
Headline figures
| Metric | Q1 FY2027 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 5.6% | — | — |
| Gross margin | 51.6% | — | — |
Guidance · company-stated
No guidance located in the held release
Margin
Capital allocation
Capex cash outflow for the quarter stood at 307 crores, which is US$32 million.
And just one last one on CAPEX.
Event summary
Reddy’s Laboratories Limited’s Q1FY27 Earnings Call July 22, 2026 Management: Mr
Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Capex cash outflow for the quarter stood at 307 crores, which is US$32 million.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
And just one last one on CAPEX.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
What’s the guidance for this year on CAPEX and for next year, please?
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Narasimham: Hopefully, that’s what is our expectation, but around that range, because, there’s continuous specific product investments in biosimilars and peptides, and then a regular CAPEX, Saion.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Strategy & priorities
Following that, Erez will share his insights on key business highlights, as well as the Company’s strategic outlook.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
We remain consistent in our strategic priorities and committed to delivering growth and profitability through disciplined execution, as the operating environment continues to evolve.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
We are focused on strengthening our base businesses and building future growth engines in peptides, biosimilars, consumer health and innovation, while pursuing targeted business development initiatives to augment our organic growth efforts.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Patient safety and product quality remain our highest priorities and will continue to guide us in every decision we make.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
The strength of our base business, and our ongoing productivity initiatives will continue to support double-digit base business growth and steady margin improvement.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Risks & headwinds
The business reported a revenue decline of 5.6% and an EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding period last year, as well as a provision of 240 crores for inventory and other costs associated with the recent semaglutide API related challenges.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
The quarter’s EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives (PLI) and other associated costs, as well as the conflict in the Middle East.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
And secondly, on today’s announcement from US President on tariffs on generics, as to how we think about the overall development?
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Even according to the Tweet, we are supposed to have two years without tariff.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
There was some discussion in the past whether, because of tariffs, we should get a CMO in the United States.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
We did engage with this issue, but tariff became not relevant.
SEC original ↗Dr Reddys Laboratories Ltd — Earnings release (6-K exhibit)EX-99Jul 29, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
43 documentsEarnings releases
40 documents- Q3 2026
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- Q2 2026
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
- EX-99RDY
Presentations
0 documentsNo presentations for Dr Reddys Laboratories Ltd are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Dr Reddys Laboratories Ltd are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.